BenevolentAI

Joerg Moeller, MD, PhD, is a Member of the Board of Directors at Secura Bio Holdings, Inc., an integrated, commercial-stage pharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. Previously, he was the Chief Executive Officer and Executive Board member of BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery. As the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee, he has successfully led large organizations in research, development, and regulatory compliance and built growth portfolios through productive and collaborative partnerships with academic institutions, biotech companies, and pharmaceutical peers. He is passionate about fostering a culture of excellence, innovation, and diversity in his teams and across the industry. He is also an advocate of digitalization and artificial intelligence as drivers of R&D efficiency and quality. Most recently, Joerg Moeller was the former Corporate Executive Vice President and Head of Global Research and Development (R&D) at LEO Pharma, a leading dermatology company. With over 30 years of experience in the pharmaceutical industry, Joerg Moeller has a proven track record of developing to successful approval innovative and competitive drugs in various therapeutic areas, such as cardiovascular, oncology, hematology, ophthalmology, dermatology, womens´health, and infectious diseases incl. a number of first-in class medicines that obtained blockbuster status.

Experienced CFO with a strong track record in start-up and scale-up companies. Proven…

I am the co-founder of Studio 84, a London-based interior design firm renowned for…